Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $19.83 USD
Change Today -0.67 / -3.27%
Volume 440.6K
ZGNX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 3:02 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

zogenix inc (ZGNX) Snapshot

Open
$20.27
Previous Close
$20.50
Day High
$21.03
Day Low
$19.41
52 Week High
07/20/15 - $21.65
52 Week Low
10/13/14 - $8.56
Market Cap
488.5M
Average Volume 10 Days
637.2K
EPS TTM
$-2.80
Shares Outstanding
24.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZOGENIX INC (ZGNX)

zogenix inc (ZGNX) Details

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product includes Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain. The company also develops ZX008, a low-dose fenfluramine for the treatment of Dravet syndrome; and Relday, an injectable formulation of risperidone that is in Phase Ib clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. It markets and sells its products to physicians, nurses, and other healthcare professionals. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

56 Employees
Last Reported Date: 08/10/15
Founded in 2006

zogenix inc (ZGNX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $387.5K
Co-Founder and Director
Total Annual Compensation: $501.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $346.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $346.3K
Compensation as of Fiscal Year 2014.

zogenix inc (ZGNX) Key Developments

Zogenix, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance for the Second Half of 2015

Zogenix, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of USD 7.367 million compared to USD 6.737 million a year ago. Loss from operations was USD 11.730 million compared to income from operations of USD 69.620 million a year ago. Loss from continuing operations before income taxes was USD 13.642 million compared to net income from continuing operations before income taxes of USD 77.536 million a year ago. Net loss from continuing operations was USD 6.696 million compared to net income from continuing operations of USD 77.536 million a year ago. Net income was USD 72.464 million compared to USD 62.864 million a year ago. Basic and diluted net income per share was USD 3.78 compared to USD 3.59 a year ago. For the six months, the company reported total revenue of USD 11.981 million compared to USD 14.126 million a year ago. Loss from operations was USD 21.529 million compared to income from operations of USD 58.340 million a year ago. Loss from continuing operations before income taxes was USD 23.794 million compared to net income from continuing operations before income taxes of USD 72.584 million a year ago. Net loss from continuing operations was USD 16.862 million compared to net income from continuing operations of USD 72.584 million a year ago. Net income was USD 49.602 million compared to USD 41.933 million a year ago. Diluted net income per share was USD 2.59 compared to USD 1.31 a year ago. For the second half of 2015, the company anticipated research and development expenses are expected to be USD 19 to USD 22 million, reflecting the initiation of ZX008 clinical studies and the recent commencement of the Relday multi-dose clinical study. Contract manufacturing revenue from the supply of Sumavel DosePro to Endo will continue at a low single-digit markup over cost of contract manufacturing. Additionally, the Company does not expect gain or loss from discontinued operations to be significant in the second half of 2015.

Zogenix, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Zogenix, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 10, 2015

Zogenix, Inc., Q2 2015 Earnings Call, Aug 10, 2015

Zogenix, Inc., Q2 2015 Earnings Call, Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZGNX:US $19.83 USD -0.67

ZGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $6.30 USD -0.10
Corium International Inc $10.77 USD +0.02
Durect Corp $2.05 USD -0.02
Egalet Corp $12.68 USD +0.08
Elite Pharmaceuticals Inc $0.21 USD +0.0099
View Industry Companies
 

Industry Analysis

ZGNX

Industry Average

Valuation ZGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.2x
Price/Book 3.3x
Price/Cash Flow 21.8x
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOGENIX INC, please visit www.zogenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.